1-氨甲基-5-甲氧基茚满
外观
![]() | |
临床资料 | |
---|---|
给药途径 | 口服 |
ATC码 |
|
法律规范状态 | |
法律规范 |
|
识别信息 | |
| |
CAS号 | 1415750-28-5 ![]() |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
化学信息 | |
化学式 | C11H15NO |
摩尔质量 | 177.25 g·mol−1 |
3D模型(JSmol) | |
| |
|
1-氨甲基-5-甲氧基茚满(英语:1-Aminomethyl-5-methoxyindane,简称AMMI),是一种由普渡大学的大卫·厄尔·尼科尔斯领导的团队开发的药物,它作为选择性血清素释放剂并与和DiFMDA具有相似亲和力的血清素转运蛋白结合。[1][2]
参见
[编辑]参考资料
[编辑]- ^ Roman DL, Saldaña SN, Nichols DE, Carroll FI, Barker EL. Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters. The Journal of Pharmacology and Experimental Therapeutics. February 2004, 308 (2): 679–87. PMID 14593087. S2CID 6439942. doi:10.1124/jpet.103.057836.
- ^ Walline CC, Nichols DE, Carroll FI, Barker EL. Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition. The Journal of Pharmacology and Experimental Therapeutics. June 2008, 325 (3): 791–800. PMC 2637348
. PMID 18354055. doi:10.1124/jpet.108.136200.